ClinicalTrials.gg
Active, not recruitingNCT05968326IMCODE003Updated Sep 9, 2026

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

A Phase 2 interventional study of Autogene cevumeran and Atezolizumab in Adenocarcinoma, Pancreatic Ductal, sponsored by Genentech, Inc.. Active, not recruiting at 87 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 307 studies in Adenocarcinoma with a site in United States — 48 open to participants now, 75 under way, 7 of them phase 3. Adenocarcinoma · United States.

Planned enrollment
37th of 271
260 · median 48
Started
2023
with 12 others
Phase 2
103 of 307
18 open now
Primary completion
2031-01
later than 68 of 73 live
Registered
262nd of 307
by date

Among the 307 studies in Adenocarcinoma with a site in United States, this one is the 37th largest by planned enrollment of the 271 interventional ones that give a count, is one of 13 that started in 2023, is one of 103 in phase 2, reaches primary completion later than 68 of the 73 other live ones, and was the 262nd registered.

Adenocarcinoma

620 studies on the registry are indexed under Adenocarcinoma; 148 are open to participants now.

Browse Adenocarcinoma studies →

Open to participants now

48 of the 307 studies in Adenocarcinoma with a site in United States are open now. Recruiting first, the newest first:

43 more — sign in →

All 48 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 111 Adenocarcinoma studies recruiting now, 82 (74%) set no upper age limit and 11 (10%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 307 studies in Adenocarcinoma with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease after surgery.

03

Conditions studied

  • Adenocarcinoma, Pancreatic Ductal

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of PDAC
  • Pancreatic cancer tumor, lymph node, (TNM) pathological staging values of T1-T3, N0-N2, and M0 per the American Joint Committee on Cancer (AJCC) Cancer Staging Manual
  • Macroscopically complete (R0 or R1) resection of PDAC
  • Unequivocal absence of disease after surgery as assessed by the investigator within 28 days prior to treatment initiation
  • CA19-9 level measured within 14 days prior to initiation of study treatment
  • Interval of between 6 and 12 weeks since resection of PDAC
  • Full recovery from surgery and ability to receive atezolizumab, autogene cevumeran, and mFOLFIRINOX in the investigator's judgment
  • Adequate hematologic and end-organ function
  • Female participants of must be willing to avoid pregnancy during the treatment period and for 28 days after the final dose of autogene cevumeran, for 9 months after the last dose of chemotherapy, and for 5 months after the final dose of atezolizumab. They must refrain from donating eggs for 9 months after the last dose of chemotherapy.
  • Male participants with a female partner of childbearing potential or pregnant female partner must remain abstinent or use specified methods during the treatment period and for 28 days after the final dose of autogene cevumeran and for 6 months after the last dose of chemotherapy. Men must refrain from donating sperm during this same period.

Exclusion criteria

Exclusion Criteria:

  • Prior adjuvant, , or induction treatment for pancreatic cancer
  • Plan for further adjuvant anti-cancer therapy for PDAC (e.g., radiotherapy and/or chemotherapy), not mandated per protocol, to be initiated after completion of mFOLFIRINOX treatment
  • Absence of spleen; distal pancreatectomy with splenectomy is exclusionary
  • Preexisting Grade >/=2 neuropathy
  • Known complete dihydropyrimidine dehydrogenase (DPD) deficiency including homozygous or compound heterozygous mutations of DPYD genetic locus associated with DPD deficiency
  • Disorders of the colon or rectum, or postoperative complication leading to Grade >/=2 diarrhea
  • Pregnancy or breastfeeding
  • Active or history of disease or immune deficiency
  • Treatment with brivudine, sorivudine, or their chemically-related analogues, which are inhibitors of DPD, within 4 weeks prior to initiation of study treatment
  • Current or planned treatment with strong inhibitors or inducers of cytochrome P450 3A4 () and/or uridine diphosphate glucoronosyltransferase 1A1 (UGT1A1).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
260 participants (estimated)

Study arms

  • Experimental
    Arm 1: Autogene Cevumeran + Atezolizumab + mFOLFIRINOX

    Participants will receive autogene cevumeran, atezolizumab and mFOLFIRINOX.

    Drug: Autogene cevumeran · Drug: Atezolizumab · Drug: mFOLFIRINOX

  • Active comparator
    Arm 2: mFOLFIRINOX

    Participants will receive mFOLFIRINOX.

    Drug: mFOLFIRINOX

Interventions

  • Autogene cevumeran will be administered intravenously (IV) at a recommended dose at specified timepoints.

  • Atezolizumab will be administered IV at a dose of 1680 milligrams (mg) at specified timepoints.

    Also known as: Tecentriq

  • DrugmFOLFIRINOX

    mFOLFIRINOX (oxaliplatin, leucovorin, irinotecan, 5-FU) will be administered IV at specified timepoints.

06

What researchers measure

Primary outcomes

  1. Disease Free Survival (DFS)

    Time frame: From randomization to first recurrence of PDAC or first occurrence of new cancer, as determined by the investigator, or death from any cause (whichever occurs first), up to approximately 6 years

Secondary outcomes

  1. DFS Rates at 12, 24, and 36 Months

    Time frame: Months 12, 24, 36

  2. Overall Survival (OS)

    Time frame: From randomization to death from any cause (up to approximately 6 years)

  3. OS Rates at 3 and 5 Years

    Time frame: Years 3 and 5

  4. Percentage of Participants With Adverse Events (AEs)

    Time frame: Up to approximately 6 years

07

Study locations

87 sites
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Jan 2031, 86 months after the start.

Of 93 phase 2 interventional studies under Adenocarcinoma, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 82. This study's planned 86 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2023
First posted
Aug 1, 2023
StartActual
Oct 18, 2023
Primary completionEst.
Jan 1, 2031
CompletionEst.
Jan 1, 2031
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05968326
Lead sponsor
Genentech, Inc.
Collaborators
BioNTech SE
Responsible party
Sponsor
First posted
Aug 1, 2023
Start date
Oct 18, 2023
Primary completion
Jan 1, 2031 (estimated)
Completion
Jan 1, 2031 (estimated)
Last update
Sep 9, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Autogene cevumeran

Start the discussion